Skip to main content
. 2022 Jul 9;10(7):1654. doi: 10.3390/biomedicines10071654

Figure 6.

Figure 6

Impacts of quercetin-loaded nanoparticles (QT-NPs) therapy on MPO: myeloperoxidase (a), CRP: C-reactive protein (b), TNF-α: tumor necrosis factor alpha (c), IFNγ: Interferon gamma (d), IL-6 and IL-10: interleukin (e,f) 14 days post DSS induction. Mean values with different letters in the same row differ significantly at p < 0.05, SE: standard error. a–e Means of the rows with different letters were significantly different among groups (p < 0.05). Control: healthy non-colitic group (rats orally gavaged with PBS). Colitic groups: DSS (rats orally gavaged with dextran sodium sulphate), DSS + QT-NPsI (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 10 mg/kg body weight for 14 days)), DSS + QT-NPsII (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 15 mg/kg body weight for 14 days)), and DSS + QT-NPsIII (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 20 mg/kg body weight for 14 days)). All groups orally gavaged by 3% DSS.